Tectonic Therapeutic, Inc. (TECX)
22.05
+0.16
(+0.73%)
USD |
NASDAQ |
Nov 10, 16:00
22.05
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 424.14M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 13.30% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 1.895 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 98.90% |
Profile
| Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA. |
| URL | http://www.tectonictx.com |
| Investor Relations URL | https://investors.tectonictx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Feb. 25, 2027 (est.) |
| Last Earnings Release | Nov. 05, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA. |
| URL | http://www.tectonictx.com |
| Investor Relations URL | https://investors.tectonictx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Feb. 25, 2027 (est.) |
| Last Earnings Release | Nov. 05, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |